Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antazoline is a first-generation antihistamine with anticholinergic properties, primarily used for the symptomatic treatment of nasal congestion and allergic conjunctivitis. It acts as a histamine H1 receptor antagonist, selectively binding to but not activating the receptor, thereby blocking the actions of endogenous histamine and providing temporary relief from symptoms such as itching, redness, and swelling associated with allergies. Antazoline is commonly formulated in eye drops—often in combination with naphazoline or tetryzoline—to treat allergic conjunctivitis. In addition to its antihistaminic effects, intravenous antazoline has demonstrated antiarrhythmic properties through multichannel action involving sodium and potassium channels; it prolongs atrial and ventricular refractory periods similar to class I antiarrhythmic agents like quinidine[1][2][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antazoline.